Oncology

Cholangiocarcinoma (CCA) is a cancer of the bile duct with poor prognosis and increasing incidence. Filippo de Braud gave an overview of CCA and its classification and highlighted key unmet needs in both diagnosis and treatment. Juan Valle explained that intrahepatic CCA (iCCA) accounts for 11% of the entire cancer of unknown primary (CUP) population, as well as 33% of patients with liver-inclusive disease.

This year’s European Organisation for Research and Treatment of Cancer (EORTC) Cutaneous Lymphoma Tumours Group (CLTG) Annual Meeting was held in Madrid, Spain. Presentations covered a broad range of topics in the field of cutaneous lymphomas, from molecular mechanisms, through diagnostics and prediction of prognosis, to skin-directed and targeted therapies, combination therapies, and patient-reported outcomes.

Ovarian cancer is the most lethal gynaecologic malignancy worldwide because of its vague presentation, insidious nature, recurrence, and drug resistance.

This article covers symposia that took place from 9th–13th September, 2022 as part of the European Society for Medical Oncology (ESMO) Congress 2022.

Despite therapeutic advances, the prognosis of non-small cell lung cancers (NSCLC) is still very poor, especially when first diagnosed at later stages involving metastases. NSCLC classification can be aided by identifying genetic, molecular, and histological subtypes that are important biomarkers in treatment selection. The majority of targeted therapies are now first-line treatment options for eligible patients with advanced stages of NSCLC.

Neratinib was developed as an irreversible catalytic inhibitor of ERBB2, which also acts to inhibit ERBB1 and ERBB4. Neratinib is U.S. Food and Drug Administration (FDA)-approved as a neo-adjuvant therapy for use in HER2+ breast cancer.

Prostate cancer varies at initial diagnosis and in its progression, with non-metastatic and metastatic presentations that may or may not respond to ADT (Figure 1).

Colorectal cancer (CRC) ranks as the third most common type of cancer in women. Patients aged 50 years and above constitute the highest percentage of patients diagnosed with the disease.